Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction – a prospective observational study

Purpose The β-1 adrenergic receptor blocker metoprolol is primarily metabolized by the polymorphic enzyme cytochrome P 450 2D6 (CYP2D6), an enzyme with substantial genetic heterogeneity. Our purpose was to investigate the impact of CYP2D6 metabolism on clinical effects and tolerability of metoprolol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 2020-05, Vol.76 (5), p.673-683
Hauptverfasser:	Anstensrud, Anne Kristine, Molden, Espen, Haug, Hans Jørgen, Qazi, Rehman, Muriq, Hysen, Fosshaug, Linn E., Spigset, Olav, Øie, Erik
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-1 Receptor Antagonists - adverse effects Adrenergic beta-1 Receptor Antagonists - blood Adrenergic beta-1 Receptor Antagonists - pharmacology Adrenergic receptors Adult Aged Biomedical and Life Sciences Biomedicine Blood pressure CYP2D6 protein Cytochrome P-450 CYP2D6 - genetics Cytochrome P-450 CYP2D6 - metabolism Cytochrome P450 Dosage Drug dosages Enzymes Female Genotype Genotype & phenotype Genotypes Genotyping Heart attacks Heart rate Hemodynamics Humans Male Metabolism Metoprolol Metoprolol - adverse effects Metoprolol - blood Metoprolol - pharmacology Middle Aged Myocardial infarction Myocardial Infarction - drug therapy Observational studies Patients Pharmacogenetics Pharmacology/Toxicology Phenotypes Physical training Prospective Studies Titration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!